The Hepatotoxicity of Valproic Acid and Its Metabolites in Rats. II. Intermediary and Valproic Acid Metabolism

G. Richard Granneman, Shyh‐Ing Wang, James W. Kesterson, Joseph M. Machinist – 1 November 1984 – The role of metabolites in valproic acid (VPA)‐associated hepatotoxicity was studied in rats. The most steatogenic mono‐unsaturated metabolite, 4‐en‐VPA, caused the greatest changes in indicators of β‐oxidation inhibition (dicarboxylic aciduria, β‐hydroxybutyrate reduction); however, the biochemical effects were much less pronounced than those reported for hypoglycin. Steatosis in VPA‐treated rats occurred only at nearly lethal doses.

HBsAg‐Serum Protein Complexes Stimulate Immune T Lymphocytes More Efficiently Than Do Pure HBsAg

Esteban Celis, Tse Wen Chang – 1 November 1984 – HBsAg from plasma of chronic hepatitis B carriers was purified by affinity chomatography using a mouse monoclonal antibody specific for HBsAg. Elution with buffer at two different pH values separated HBsAg into two fractions: one contained high amounts of immune complexes associated with HBsAg; the other contained larger quantities of the HBsAg polypeptides P24 and GP27 and only small amounts of immunoglobulin.

Early Structural and Functional Changes in Liver of Rats Treated with a Single Dose of Valproic Acid

Anne Marie Jezequel, Patrizia Bonazzi, Giuseppe Novelli, Cinzia Venturini, Francesco Orlandi – 1 November 1984 – Valproic acid (VPA) is a simple fatty acid largely used as anticonvulsivant agent. Side effects are uncommon, but cases of fatal hepatic failure have been reported. To elucidate the mechanism of VPA‐induced hepatotoxicity, the functional and structural changes associated with administration of sodium valproate (NaVPA) to rats (200 or 600 mg per kg, i.p.) were analyzed.

Protective Effect of 4–(3,7,11,15‐Tetramethyl‐6,10,14‐Hexadecatrienoyl)Morpholine on Liver Injury Induced by Hepatotoxins in Rats

Kenji Fujiwara, Yasuhiko Ohta, Itsuro Ogata, Yuzuru Sato, Yuji Oka, Shigeki Hayashi, Katsuyoshi Takatsuki, Hiroshi Oka – 1 November 1984 – The effect of 4–(3,7,ll,15‐tetramethyl‐6,10,14‐hexadecatrienoyl)morpholine (E‐0712), a new synthetic compound, on liver injury induced by two hepatotoxins in rats was studied. Oral doses of E‐0712 four times at 0, 6, 12 and 18 hr significantly attenuated elevated SGPT values and prolonged prothrombin time (PT) at 24, 36, 48, 60 and 72 hr in rats with a single s.c. dose of D‐galactosamine in which SGPT values and PT reached the peak within 48 hr.

The Fate of Polymeric and Secretory Immunoglobulin A After Retrograde Infusion into the Common Bile Duct in Rats

Albert L. Jones, Gary T. Hradek, Douglas L. Schmucker, Brian J. Underdown – 1 November 1984 – In the rat, plasma IgA is rapidly endocytosed by hepatocytes and translocated to the bile via a receptor‐mediated vesicular transport system which appears to remain intact even during cholestasis. During the latter phenomenon, there is an accumulation of secretory IgA (sIgA) in plasma. These data suggest that biliary IgA can be regurgitated into the plasma compartment. The present study was designed to determine the location and mechanism(s) by which this might occur.

HLA‐DR Antigens in HBsAg‐Positive Chronic Active Liver Disease with and without Associated Delta Infection

Barbara Forzani, Giovanni C. Actis, Giorgio Verme, Antonio Amoroso, Iolanda Borelli, Emilio S. Curtoni, Maria Grazia Rumi, Antonio Picciotto, Giovanni Marinucci, Maria Antonietta Freni, Mario Rizzetto – 1 November 1984 – The A, B, C and DR locus specificities of the human leukocyte antigens system (HLA) were determined in 45 delta‐positive and 44 delta‐negative Italian patients, all with HBsAg‐positive chronic active liver disease; controls were 526 healthy Italian blood donors matched for age, sex and geographical origin. HLA‐A, B, C gene frequencies were not significantly changed.

In Vivo Interactions Between H2‐Receptor Antagonists and Ethanol Metabolism in Man and in Rats

Helmut K. Seitz, Siegrid Veith, Peter Czygan, Johann Bösche, Bernd Simon, Roland Gugler, Burkhard Kommerell – 1 November 1984 – The influence of a 7‐day medication of either cimetidine (1,000 mg per day) or ranitidine (300 mg per day) on serum ethanol concentrations after a single oral dose of ethanol (0.8 gm per kg body weight) was investigated in a randomized placebo‐controlled study in eight male volunteers. Compared with the placebo, cimetidine but not ranitidine produced a significant increase in both the peak serum ethanol concentration (85.9 ± 3.5 vs.

Subscribe to